[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Phoenix Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":140},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,90,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100365606","phase-4-continuous-vs-intermittent-ketorolac-for-pain-control-in-peds-cv-surgery-100365606",false,"NCT04040452","Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery","Continuous Infusion Versus Intermittent Ketorolac for Postoperative Pain Control in Pediatric Cardiac Surgery Patients","CIVIK","Inclusion Criteria:\n\n1. All patients aged 3 months to 4 years 11months admitted post operatively to the CVICU during the time period in which the study will be ongoing\n2. Initiation of study medication within the first 12-24 hours post-operatively\n3. The cardiovascular attending of record after review of the intraoperative course and post-operative laboratories determines the patient will receive Ketorolac for pain control\n\nExclusion Criteria:\n\n1. Patients that have acute kidney injury, as defined by the letter \"I\" in the pRIFLE criteria.\n2. History of allergy or sensitivity reaction to ketorolac or any NSAID medications.\n3. Requiring mechanical circulatory support (ECMO) or continuous renal replacement therapy (CRRT) within the first 48 hours post-operatively\n4. Orthotopic heart transplantation\n5. Clinically significant bleeding\n6. Patients with known pre-operative medical renal disease, renal transplantation history, congenital or acquired renal abnormality or deformity","ALL","3 Months","59 Months",{"count":21,"type":22},166,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The proposed study will be a prospective, randomized, double blind, placebo controlled trial to compare the use of a continuous infusion versus intermittent ketorolac on postoperative patients in the pediatric cardiovascular ICU. We intend to determine if the continuous infusion leads to a decreased utilization of opiates when compared to intermittent ketorolac.",[28],"Congenital Heart Disease in Children",[30,31,32,33,34,35],"pain control","cardiac surgery","pediatric","opioid","NSAID","congenital heart disease","RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-27","ACTUAL",{"date":42,"type":40},"2021-03-01",{"date":44,"type":22},"2026-12-01",{"name":46,"class":47},"Phoenix Children's Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":48},"100544696","phase-2-a-clinical-trial-of-soluble-fiber-for-asthma-100544696","NCT06372249","A Clinical Trial of Soluble Fiber for Asthma","A Phase ll Randomized Controlled Trial of Soluble Fiber for Asthma","Inclusion Criteria:\n\n* Between ages 6-17\n* Asthma diagnosis within the last 2 years\n* Fractional excretion of exhaled nitric oxide (FeNO) \\> 50 ppb OR a clinical history of environmental allergies as defined by a positive skin prick or positive specific immunoglobulin E (IgE) tests to aeroallergens\n* No emergency department visits in the past 1 month\n* Ability to consume a liquid drink of fiber or placebo\n* Ability to return for a 4-6 week follow-up visit\n* No special or unique diet\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* Bronchiectasis\n* Change in asthma medicines other than short acting bronchodilators planned over the next 4-6 weeks\n* Baseline estimated daily fiber intake less than or equal to 16 grams as determined by the ASA 24\n* Sibling of a participant already enrolled in the study","6 Years","17 Years",{"count":59,"type":22},105,[61],"PHASE2","Randomized controlled trial of soluble fiber (Fruitafit Inulin). Participants will complete an ASA 24 dietary recall questionnaire to access their fiber intake. If eligible for the study, participants will be supplemented to their target fiber dosage with either soluble fiber (Fruitafit Inulin) or placebo. Collection of blood serum, fecal samples, and nasal wash will aid in analyzing the microbes present in one's gut and how fiber and diet may impact it. Thus, allowing researchers to better understand the pathways that may connect diet and asthma and if it is possible to improve asthma by altering one's diet.",[64],"Asthma in Children",[66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Asthma","Mild Asthma","Moderate Asthma","Severe Asthma","Allergies","Environmental Allergies","Controlled Asthma","Well-Controlled Asthma","Diet","Dietary Fiber","Dietary Supplementation","Micro-biome","Gut-microbiome","Children","Child","Microbiome Analysis","2026-03-02",{"date":84,"type":40},"2026-03-04",{"date":86,"type":40},"2025-11-10",{"date":88,"type":22},"2027-05-31",{"name":46,"class":47},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":95,"conditions":105,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":48},"100570709","ovarian-tissue-cryopreservation-100570709","NCT06710769","Ovarian Tissue Cryopreservation","Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen","OTC","Inclusion Criteria:\n\n* Newly diagnosed or relapsed malignancy with proposed treatment regimen containing at least ONE (1) of the following:\n\nwhole abdomen or pelvic irradiation\n\ntotal body irradiation\n\nProposed treatment regimen to include any of the following:\n\ncyclophosphamide equivalent dose (CED, see Green et al 2014) ≥7.5 g\u002Fm2\n\nany treatment regimen containing procarbazine\n\nbone marrow transplant conditioning regimen containing alkylators\n\nOR health condition or malignancy that requires removal of one or both ovaries. Health status adequate to undergo elective laparoscopic surgery (as per anesthesiologist assessment)\n\nExclusion Criteria:\n\n* Pregnancy or a patient who is currently breastfeeding\n\nPatients who are eligible for and agree to oocyte preservation\n\nAnyone deemed high risk for complications from the surgery and\u002For anesthesia.\n\nAnyone unable to provide consent due to psychiatric conditions or cognitive delay (in parent\u002Fguardian for patients \\\u003C18 years, and patient \\>18 years)","FEMALE","1 Year","25 Years",{"count":102,"type":22},40,[104],"NA",[106],"Infertility, Female","2026-01-22",{"date":109,"type":40},"2026-01-23",{"date":111,"type":40},"2020-07-30",{"date":113,"type":22},"2031-07",{"name":46,"class":47},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":121,"enrollmentInfo":122,"targetDuration":124,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},"100213403","modulation-of-molecular-fingerprinting-in-pediatric-sepsis-100213403","NCT02055105","Modulation of Molecular Fingerprinting in Pediatric Sepsis","Inclusion Criteria:\n\n* Age 1 through 18 years\n* Patients admitted to the PICU with concerns for sepsis or those developing sepsis during their admission to the hospital.\n* Patients must be enrolled int he study from arrival time tot he ED up to 24 hours from the time of initiation of antibiotic therapy for treatment of sepsis or septic shock.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients \\\u003C1 year of age and greater than 18 years of age.","18 Years",{"count":123,"type":22},50,"5 Days","OBSERVATIONAL","The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.",[128],"Systemic Inflammatory Response Syndrome",[130],"Pediatric Sepsis","2025-11-07",{"date":133,"type":40},"2025-11-12",{"date":135,"type":4},"2014-03",{"date":137,"type":22},"2027-10",{"name":46,"class":47},2,""]